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Abstract 
The photosynthetic bacteria Rhodobacter sphaeroides has been studied as a functional food source; however, in this 
clinical study, we report for the first time its use as a treatment for atopic dermatitis. Topical cream containing 10% 
(v/v) extract was demonstrated to have the ability to reduce skin moisture content loss and pruritus by 27.82% in 
clinical trials for atopic dermatitis compared with controls. In particular, there were statistically significant differences 
in the pH and temperature changes of the skin, skin firmness and general skin appearance. Changes in the skin pH 
were measured as 4.83, and there was a 3.37% change in temperature after 4 weeks of treatment. It was also found 
that there were great differences in wrinkle states according to the grading scale of patients before and after treat‑
ment with topical cream. Therefore, these results strongly suggest that extracts from photosynthetic bacteria can be 
employed to soothe atopic irritation as a new cosmetic bioresource.
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Introduction
Due to atmospheric pollution and changes in residen-
tial environments resulting from the rapid industriali-
zation of modern society, the number of patients with 
atopic dermatitis has been recently increasing. Atopic 
dermatitis is a skin disease that may occur in any age 
group that is characterized by severe itch resulting 
from chronic inflammatory eczema. Genetic factors are 
strongly related to this disease, and stress, changes in 
external environments, and infection are major causes 
of atopic dermatitis aggravation. A major symptom of 
atopic dermatitis is severe itch, and this disease induces 
abrasions, erythematous eruption, blisters, and various 
lesions (Shultz and Hanifin 2002). Because the cause of 
the symptoms for atopic dermatitis has not been clearly 
established (Bos et  al. 1992), studies of the cause have 
been unceasingly conducted. Although the management 
of environmental conditions that may be problematic 
and drug treatment centering on steroids and antihista-
mines are used as major treatment methods (Park et al. 
2002), the symptoms of this disease are only temporar-
ily relieved, and the aggravation and relief of symptoms 
are repeated. In addition, adverse affects to some exter-
nal application products are emerging. Therefore, recent 
studies have mainly been conducted using products 
for external application containing oriental medicinal 
extracts with natural materials that enhance moisturizing 
effects as therapeutic agents for atopic dermatitis (Hong 
and Jung 2014). Although clinical effects from extracts 
from various natural products used as atopic dermatitis 
treatment materials have been demonstrated, no clear 
solution has been presented until now. Therefore, among 
the microorganisms that may be easily produced due to 
their ability to be cultured in large numbers, we aimed to 
identify the effects of the photosynthetic bacteria Rhodo-
bacter sphaeroides on atopic dermatitis.
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There have been reports indicating that the faculta-
tive anaerobic photosynthetic bacteria Rhodobacter 
sphaeroides produces SOD (superoxide dismutase) (Kim 
and Lee 2004). SOD is an anti-oxidant enzyme that has 
been reported to convert harmful oxygen radicals in the 
body into H2O2, and it has oxidation inhibitory functions 
via its conversion into water and oxygen by catalase to 
remove harmful active oxygen in vivo, thereby protecting 
living bodies (Cho and Choi 2013; McCord and Fridovich 
1969). Although diverse studies on aging and disease have 
been conducted using eukaryotic organisms as materials, 
studies on microorganisms existing in the natural world 
in large numbers are insufficient. In addition, although 
photosynthetic bacteria have the abovementioned effects 
due to their ability to generate hydrogen, they are mainly 
studied for their function in alternative clean energy 
(Lee 1986), for use as materials in environmental indus-
tries such as livestock manure treatment and waste water 
purification, and for utilization as foods because they 
contain large amounts of nutrients (Lee and Lee 2000). In 
addition to studies on photosynthetic bacteria performed 
thus far, we utilized the established strengths of photo-
synthetic bacteria i.e., their production of SOD and cata-
lase and their rich nutrients, to explore new functions of 
photosynthetic bacteria in relieving skin ailments such as 
atopic dermatitis by supplying nutrients to the skin and 
removing harmful active oxygen from the body with the 
view of preparing a new horizon for photosynthetic bac-
teria. In addition, we conducted clinical trials for the first 
time using a formulation for atopic dermatitis to identify 
the value of photosynthetic bacteria for the treatment of 
this disease.
Materials and methods
Preparation of a topical cream for clinical trials
To first make extracts of photosynthetic bacteria, Rho-
dobacter sphaeroides (ATCC, 21286™, Manassas, VA, 
USA) was grown with culture medium (ATCC® Medium 
550: R 8 A H medium, ATCC, Manassas, VA, USA) and a 
20 W fluorescent lamp in a five liter glass flask at pH 6.8 
and 30°C by agitating at 100 rpm. After 5 days of cultiva-
tion, the cells were collected from the culture broth and 
broken by a sonicator (AUG-R3-900, Asia Ultrasonic, 
Bucheon, Korea) for 1  h. Then, the supernatant was fil-
tered by filter paper (5C 110 mm, ADVANTEC, Dublin, 
CA, USA), and the filtrate was used as a photosynthetic 
bacteria extract by mixing 10% (v/v) of the extract with 
a basal formulation of a topical cream as described in 
Table 1 for a test topical cream.
For more detailed processing for making the topical 
cream, the water phase was heated to 80–85°C to become 
transparent. Afterward, a carbopol #940, as a thickner 
I was added. A preservative, oil part I, and 10% (v/v) of 
photosynthetic bacteria extract were placed in the oil 
part in order and heated to 85–90°C. Afterward, after 
confirming that oil part I was completely melted, oil part 
II was added at 80°C. The oil part was continuously mixed 
until the oil phase was completely dissolved with a pad-
dle mixer at 900–1,000 rpm. After confirming that the oil 
part content was completely dissolved, the oil part was 
added to the water phase at 75–80°C to conduct the 1st 
emulsification. Afterward, the solution was homogenized 
Table 1 The formulation of  a topical cream used for  clini-
cal trials
Classification Materials Content (%)
Rhodobacter sphaeroide extracts Culture medium 10





Thickner I Carbopol # 940 0.09
Antiseptic D‑M 0.18
D‑P 0.09















Oil II Borage seed oil 0.27
DC345 1.8
Extract Germall 115 0.18
Vitamin E acetate 0.45
Allantoin 0.09
DL‑panthenol 0.18





pH controller TEA 0.126
Thickner II Rheocare ATH 0.18
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3 min using a homo mixer at 4,000–4,500 rpm. When the 
homogenization was completed, the extract and a fra-
grance was added to the solution at 55°C, and the solu-
tion was again homogenized for 5  min using a homo 
mixer at 4,000–4,500 rpm. A pH conditioning agent was 
added at 45–50°C, and the solution was again homoge-
nized for 3 min using a homo mixer at 3,500–4,000 rpm. 
Finally, Rheocare ATH was added to the solution, and the 
solution was homogenized for 5 min using a homo mixer 
at 3,500–4,000 rpm to make the formulation.
As a negative control, the cream containing the same 
basal formulation in Table 1 without only the photosyn-
thetic bacteria extract was used since this formulation is 
commonly used for the base of most topical creams in 
Korea (Yu et al. 2004). For a positive control, commercial 
product (expressed as a control product in this work), a 
Atopalm® mile cream (ATOPALM, Daejeon, Korea) was 
used in the experiments, and the composition of major 
components was as follows: glycerin, propanediol, myris-
toyl, capric tryglyceride, polyglyceryl-10 distearate, glyc-
eryl stearate, cetearyl alcohol, grape seed oil (3%, v/v), 
jojoba seed oil, Portulacae Herba extract (5%, v/v), sorbi-
tan stearate, olive oil, hydrogenated vegetable oil, phytos-
terol, sodium hyaluronate (1%, w/v), tocopheryl acetate, 
allantoin, stearic acid, carbomer, arginine, dimethicone, 
1,2-hexanediol, and caprylyl glycol, tropolone, etc.
Evaluation of the clinical efficacy for atopic dermatitis
Patients
The efficacy of the formulation for atopic dermatitis was 
examined among males and females between two and 
40  years old who had itching symptoms due to xero-
derma. The detailed information of the patients in the 
clinical trials is shown in Table 2. In the clinical trials, the 
relevant test product was applied to dry areas before the 
water was dried out after washing the face two times per 
day for 4  weeks. The water content of the test product, 
the amount of trans-epidermal water loss, skin tempera-
ture, skin pH, VAS, and SCORAD Index (atopic dermati-
tis symptom index) were evaluated similarly to previous 
studies (Young and Choi 2005; Yu et al. 2004).
Measurement of the skin moisture content 
and trans‑epidermal water loss
Skin moisture content was measured from the skin of 
test subjects who used the test formulation for 0–4 weeks 
with a corneometer (GmbH, Cologne, Germany) (Yu 
et al. 2004) by placing the corneometer probe into con-
tact with the skin, and the average value of five measure-
ments was used. The amount of trans-epidermal water 
loss was also measured from dry areas of the skin of test 
subjects who used the photosynthetic bacteria formula-
tion for 0–4 weeks using a Vapometer (Delfin Technolo-
gies Ltd, Kuopio, Finland), which measures the amount of 
trans-epidermal water loss based on the Fick’s law for dif-
fusion, and lower values indicated better skin conditions.
The changes of pH and temperature of the patient skin
Skin pH was measured with a skin pH meter (PH905, 
Courage-Khazaka electronic GmbH, Cologne, Germany) 
because the acid mantles in the skin play the role of anti-
biotic defensive barriers. Therefore, if the pH of the skin 
increases, the possibility of skin inflammation due to 
various bacteria also increase. Skin temperature was also 
measured with a skin thermometer (ST500, Courage-
Khazaka electronic GmbH, Cologne, Germany), which 
is a device used to measure skin temperature by sensing 
infrared rays emitted from the atopic dermatitis areas of 
the skin.
General high‑resolution photograph acquisition
Photographs of atopic dermatitis regions of test subjects 
were taken before and after treatment (for 4 weeks) with 
the topical cream by a high-resolution camera (D3300, 
Nikon, Tokyo, Japan).
Measurement of Visual Analogue Scale (VAS) for the relief 
of pruritus
The test subjects were instructed to mark the degree of 
itch they felt on a 10 cm line by indicating higher degrees 
with longer lines, and the lengths marked were measured. 
VAS evaluation for pruritus was conducted by comparing 
the lengths of the lines indicating the degree of pruritus 
before and after treatment with the topical cream (Hong 
et al. 2008).
Measurement of the Scoring Atopic Dermatitis (SCORAD) 
index
The SCORAD index (Stalder and TaÏeb 1993) was modi-
fied to evaluate the areas of atopic dermatitis symptoms 
and the degree of the symptoms in the head, trunk, arms, 
and legs. This experiment was conducted by dermatolo-
gists, and subjective symptoms were evaluated by medi-
cal examinations through interviews.
Table 2 Groups of the patients participating in the clinical 
trials





Page 4 of 9Kim et al. AMB Expr  (2015) 5:49 
Statistical analysis
All experimental data were performed in triplicate and 
processed by two-way ANOVA using the software Statis-
tical Analysis System (SAS). The minimum difference in 
significance level was set to p < 0.05.
Results
Measurement of the water content of skin
The results of observing the changes in skin water con-
tent after using the clinical formulation are shown in 
Fig.  1 by comparing those from the control product (a 
positive control using a commercial product). The results 
from the negative control did not show any improvement 
even after 4 weeks treatments. (Therefore, any data were 
not shown in this wok except for the visual comparison 
in Fig. 2).
Upon reviewing the results, it can be observed that the 
skin water content increased at 2 and 4 weeks of use of 
the products compared with before using the products 
in the group that used the clinical trial formulation and 
the control group. In the case of the test formulation, 
the water content increased by 51.85% after 5  weeks of 
use compared with before using the formulation, and it 
increased by 79.44% after 4 weeks of use. Given that in a 
previous study of the effects of oriental medicinal materi-
als on atopic dermatitis the skin water content increased 
by approximately 21% 6  weeks after use compared with 
before using the materials, the photosynthetic bacteria 
clinical formulation used in this study may be judged as 
being effective for water content (Kang et al. 2009). In the 
control group, the water content increased 36.62% after 
2  weeks of use and 51.18% after 4  weeks of use. Com-
pared with the control group, the group that used the 
clinical trial formulation had 15.23% higher water con-
tent after 2 weeks of use and 28.26% higher water content 
after 4 weeks of use. Although both the control product 
and the photosynthetic bacteria clinical trial formula-
tion included materials helpful for skin water content 
as part of materials needed for their formulation, given 
that these materials are generally necessary for cosmetic 
formulation and the differences between the two are 
remarkable, it can be judged that the clinical trial formu-
lation is much more effective for skin water content than 
existing products.
Measurement of the amount of trans‑epidermal water loss
To determine the skin water content, the amount of 
trans-epidermal water loss was measured, and the results 
are shown in Table 3. In (A) is shown the amount of water 
loss after 2 and 4 weeks of use compared with before use 
of the products in the clinical trial formulation and con-
trol groups. As with skin water content, the effects were 
more remarkable in the clinical trial formulation group 
compared with the control group. In previous atopic 
dermatitis-related clinical studies in which the effects of 
glucan and ceramide were examined, the water content 
decreased by 13–17 after 4 weeks of use, which is simi-
lar to the values of 14–15 found in this study; thus, the 
effects could be confirmed (Yu et al. 2004). After 2 weeks 
of use, the clinical trial formulation group showed a 
trans-epidermal water loss rate of change of 15.81%, 
while the control group had a rate of change of only 
Fig. 1 The changes of skin moisture content of the patients. Mean values ±SD from separate triplicate experiments are shown. Means with dif‑
ferent letters (A–C) within same sample are significantly different at p < 0.05, and means with different letters (a–b) within the same period are 
significantly different at p < 0.05.
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5.50%. After 4 weeks of use, the clinical trial formulation 
group demonstrated a decrease in the amount of trans-
epidermal water loss of 27.82% compared with before 
using the formulation, while the control group demon-
strated a lesser decrease in the amount of trans-epider-
mal water loss of 10.49%. The above results indicate that, 
compared with existing products, the clinical trial formu-
lation is effective for skin water retention because it pre-
vents trans-epidermal water loss more effectively.
Changes in the temperature and pH of the skin
Because there was a previous study indicating that if 
skin surface temperatures increase, the amount of trans-
epidermal water loss also increases (Min et al. 1996), the 
Fig. 2 Comparison of the skin of the legs of the patients before and after 4 weeks of treatment with the negative control product (1), the positive 
control product (2) and the test product (3).
Table 3 Measurement of  the trans-epidermal moisture 
loss in the skin
Mean values ±SD from separate triplicate experiments are shown. The means 
with different letters (A–C) within the same sample are significantly different 
at p < 0.05, and means with different letters (a–b) within the same period are 
significantly different at p < 0.05.
Period (weeks) Test product (g/h m2) Control product (g/h m2)
(a) Trans‑epidermal moisture loss
 0 20.31 ± 7.38Aa 19.45 ± 6.84Aa
 2 17.10 ± 6.64Ba 18.38 ± 5.52Bb
 4 14.66 ± 7.31Ca 17.41 ± 5.40Bb
(b) The percentage of the trans‑epidermal moisture loss changes from 
the zero day of the treatment
 2 15.81% 5.50%
 4 27.82% 10.49%
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skin temperature was determined and compared with the 
clinical trial formulation treatment time to further verify 
the trans-epidermal water loss. The test subjects’ skin 
temperatures decreased after 4 weeks of treatment with 
the formulation (Table 4). In the case of the clinical trial 
formulation group, the relevant change rates were 0.24% 
after 2 weeks of use and 3.37% after 4 weeks of use, indi-
cating insignificant effects on temperature reduction. In 
a previous study in which skin temperature was measure 
to determine the effects of an existing oriental medicinal 
cosmetic material made from a golden thread detoxifying 
decoction, the oriental medicinal cosmetics material did 
not affect skin temperature (Yun et  al. 2008). Skin tem-
perature is considered to vary greatly among individu-
als. Similarly, in the case of the control group, there were 
almost no temperature reduction effects with a change 
rate of 0.43% after 2  weeks of use and a change rate of 
2.86% after 4  weeks of use. Although the temperature 
reduction effects of the clinical trial formulation were 
greater compared with the control group, the differences 
were small. Therefore, the clinical trial formulation was 
concluded to have almost no skin temperature reducing 
effect.
Based on a previous study (Oh et  al. 2010) indicating 
that younger and healthier skin should have pH levels 
closer to slight acidity, and skin with atopic dermatitis are 
alkaline due to damage to skin barriers, skin pH measure-
ment experiments were conducted to further validated 
the skin water-retaining effects of the clinical trial formu-
lation. Changes in the pH levels appearing in the clinical 
trial formulation and control groups could be identified 
until after 4 weeks of use for the formulations (Fig. 3). The 
pH levels decreased after 2 and 4 weeks of use in the clin-
ical trial formulation group but decreased after 2 weeks 
of use and increased after 4 weeks of use for the control 
group. In a previous study in which clinical tests of cos-
metics comprising oriental medicinal materials for atopic 
dermatitis were conducted, the skin pH level increased 
from 5.4 before treatment to 5.6 after treatment; thus, the 
skin became slightly acidic (Kang et al. 2009). Similar to 
that study, although the difference between the clinical 
trial formulation and control groups was small, the clini-
cal trial product maintained slight acidity of the skin with 
a pH close to 5 and could have good effects against atopic 
dermatitis that shows alkalinity.
Evaluation of the pruritus VAS and SCORAD index
VAS evaluation was conducted by having the test subjects 
mark their degree of pruritus using a 10 cm-long line as 
a pruritus scale. Fig 4 shows that, for of the formulation 
used in the clinical trial, the pruritus felt by the test sub-
jects that was 5.1 cm on the pruritus scale before using 
the formulation, and it was reduced to 4.4 cm by 0.7 cm 
when the formulation was used for 4  weeks. However, 
the general control product showed a change of 2.1 from 
4.8 cm at the beginning to 2.7 cm after 4 week s of use. 
Therefore, it can be observed that the pruritus reducing 
effect of the clinical trial formulation was smaller com-
pared with the control product.
The SCORAD index, which enables determining the 
severity of dermatitis, was evaluated for the test sub-
jects to identify the effects of the clinical trial formula-
tion (Sung et al. 2014). The SCORAD index values after 
treating the clinical trial formulation and positive con-
trol sample were estimated as ca. 20 at 2  weeks of the 
treatment, and at 4  weeks of the treatment they were 
decreased further down to 17.05 and 16.95 for the clinical 
trial formulation and the positive control groups, respec-
tively, but the difference was not significant between two 
groups. It could tell that about 21% improvement could 
be observed after 4 weeks treatment of both samples in 
terms of SCORAD index, compared to the starting day 
(Table 5b). Another study verifying the effects of cosmet-
ics made of oriental medicinal materials reported that the 
SCORAD index value after applying cosmetics made of 
oriental medicinal materials for 6  weeks was 15, which 
is not much different from the value we found in this 
study although the application period of the product was 
2 weeks longer than the period in this study (Kang et al. 
2009). Because the SCORAD index decreased over time 
after applying the product to the test subjects, the atopic 
dermatitis-relieving effects of the clinical trial formula-
tion were examined, but we could not conclude that the 
effects were better compared to existing products.
Photographic observation of the atopic dermatitis regions 
before and after the treatments
The pictures taken from the same areas of the patients 
before and after the treatments are shown in Figs.  5 
(arms), 2 (legs). In a negative control (1 in Figs.  5, 2), 
Table 4 Measurement of the skin temperature upon treat-
ment with the topical cream
Mean values ±SD from separate triplicate experiments are shown. Means with a 
different letter (A) within the same sample are significantly different at p < 0.05, 
and means with a different letter (a) within same period are significantly 
different at p < 0.05.
Period (weeks) Test product (°C) Control product (°C)
(a) Skin temperature
 0 30.46 ± 1.19Aa 30.44 ± 0.84Aa
 2 30.38 ± 7.14Aa 30.31 ± 0.74Aa
 4 29.41 ± 1.04Aa 29.57 ± 0.90Aa
(b) The percentage of skin temperature changes from the zero day of the 
treatment
 2 0.24% 0.43%
 4 3.37% 2.86%
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there was no improvement observed even after 4 weeks 
treatment. However, great improvement was observed 
for both legs and arms after 4 weeks treatment in using 
the test products even though there was some enhance-
ment was also observed in treating the control products 
(commercial products), and there was particularly better 
efficacy in the legs, which was possibly due to the rela-
tively soft skin of the inner portions of the arms. It can 
be observed that xeroderma and inflammation were 
relieved after using the formulation for 4 weeks, and the 
skin became clear for many patients. The skin of the leg 
in Fig. 2 also shows that the atopic dermatitis symptoms 
were relived; thus, the effects of the formulation used 
in the clinical trial could be identified. Therefore, these 
results could tell that the effects of the test product on 
soothing atopic dermatitis were found to be better than 
those of the commercial product used in this work. This 
clinical efficacy of the topical cream also seems to be sim-
ilar to or even better than those shown by other cosmetic 
containing the extracts from snail mucus (Oh et al. 2010).
Fig. 3 Comparison of skin pH changes for treatment with the cream. Mean values ±SD from separate triplicate experiments are shown. Means 
with a different letter (A) within the same sample are significantly different at p < 0.05, and means with a different letter (a) within the same period 
are significantly different at p < 0.05.
Fig. 4 The assessment of the pruritus index of atopic dermatitis 
patients. Mean values ±SD from separate triplicate experiments are 
shown. Means with different letters (A–B) within the same sample 
are significantly different at p < 0.05, and means with different letters 
(a–b) within the same period are significantly different at p < 0.05.
Table 5 Evaluation of  the SCORAD index after  treatment 
with the topical cream
Mean values ±SD from separate triplicate experiments are shown. Means with 
different letters (A–C) within the same sample are significantly different at 
p < 0.05 and means with a different letter (a) within same period are significantly 
different at p < 0.05.
Period (weeks) Test product Control product
(a) SCORAD index
 0 21.76 ± 6.07Aa 21.59 ± 8.24Aa
 2 20.00 ± 7.14Ba 20.00 ± 7.87Ba
 4 17.05 ± 8.00Ca 16.95 ± 7.60Ca
(b) The percentage of SCORAD index changes from the zero day of the 
treatment
 2 8.09% 7.36%
 4 21.65% 21.49%
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Discussion
In this study, the efficacy of the extracts from photo-
synthetic bacteria for relieving atopic dermatitis was 
clinically demonstrated for the first time in the form of 
a topical cream. The topical cream containing 10% (v/v) 
extract demonstrated more beneficial effects for skin 
water content and the amount of trans-epidermal water 
loss. This result also indicated that this unique formula-
tion could relieve xeroderma, which is a general symp-
tom of atopic dermatitis, and it may also be effective 
for treating atopic dermatitis. Together with maintain-
ing large skin water content, this cream was capable of 
maintaining relatively low skin temperature, which could 
reduce the feeling of itch in the skin. The pH of the skin 
was also maintained as slightly acidic with the treat-
ment with this cream because healthier skin is closer to 
being slightly acidic and the potential of the formulation 
as a countermeasure against atopic dermatitis, which is 
characterized by alkaline skin, was reported (Yun et  al. 
2008). From these results, it appears that topical creams 
containing the extracts from photosynthetic bacteria 
should be effective for treating or at least soothing atopic 
dermatitis although some of the formulation chemicals 
(glycerin, Jojoba oil, SC-glucan) in Table 1 could possibly 
affect skin water content retention and skin protection. 
However, the amount of these chemicals is small enough 
to be negligible for influencing efficacy compared with 
other commercially available cosmetics. With regards 
to the SCORAD index of this trial, the values decreased 
over time after the use of the topical cream, and these 
results are similar to or even better that that of existing 
cosmetics.
Based on the above results of pH and water contents 
changes as well as SCORAD index, it could tell that the 
effects of the test topical cream for relieving atopic der-
matitis may be attributed to the removal of reactive oxy-
gen species (ROS) in the skin, which is a major cause of 
inflammation by the super oxide dismutase (SOD) and 
catalase produced by photosynthetic bacteria (Cho and 
Choi 2013). Therefore, it is very positive that the pho-
tosynthetic bacteria formulation in this cream showed 
remarkable enhancement, compared to those of com-
mercially used topical cream for atopic dermatitis. How-
ever, interestingly enough, the VAS scales for pruritus felt 
by the patients did not improve much in the clinical trial 
compared with existing cosmetics, which should also be 
Fig. 5 Comparison of the skin of the arms of the patients before and after 4 weeks of treatment with the negative control product (1), the positive 
control product (2) and the test product (3).
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considered when applying this cream to a broad spec-
trum of patients.
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